65,437 trials
Atrophy · Vaginal Diseases
Primary: Mean Change From Baseline in the Most Bothersome Vulvar and Vaginal Atrophy (VVA) Symptom (MBS) of Vaginal Dryness — -1.22; -1.26; -0.84 Units on a scale
Atrophy · Vaginal Diseases
Primary: Mean Change From Baseline in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear — -3.0; -2.8; -24.1; -26.8 percentage of parabasal cells
Chromophobe Renal Cell Carcinoma · Clear Cell Renal Cell Carcinoma · Papillary Renal Cell Carcinoma
Primary: Maximum Tolerated Dose (MTD) of BAY 43-9006 (Sorafenib)in Combination With Bevacizumab (Phase I) — 200 mg
Atrophy · Vaginal Diseases
Primary: Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear (Dryness Strata) — -3.7; -31.7 percentage of parabasal cells
Bipolar Disorder
Primary: Overall Change in Bipolar Illness Severity as Measured by Clinical Global Impression for Bipolar Disorder Severity (CGI-BP-S) Score — -1.22; -1.48 units on a scale…
Rheumatoid Arthritis
Primary: Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24 — 23.3; 54.5; 50.6 percentage of participants
HIV Infection · Hepatitis B
Primary: Sero-response to Hepatitis B Surface Antigen — 60; 73.2; 75.4 percentage of participants who resonded — p=0.0440
Atrophy · Vaginal Diseases
Primary: Incidence of Adverse Events (AEs) — 38; 44; 22; 11 Participants
Atrophy · Vaginal Diseases
Primary: Incidence of Adverse Events (AEs) — 220; 67; 34; 13 Participants
Adenocarcinoma of the Lung · Adenosquamous Cell Lung Cancer · Bronchoalveolar Cell Lung Cancer
Primary: Time to Progression — 4.63 months
Atrophy · Vaginal Diseases
Primary: Mean Change From Baseline in Percentage of Parabasal Cells in Maturation Index of Vaginal Smear — 5.0; -46.0 percentage of parabasal cells
Pathological Processes in the Posterior Fossa · Dura Defects
Primary: Incidence of Cerebrospinal Fluid (CSF) Leakage Observed After Surgery — 74.07; 78.13 percentage of participants — p=0.7159
Adrenal Cortex Neoplasms
Primary: Response Rate (RR) of Axitinib Administered Daily, in Patients With Recurrent, Metastatic, or Primary Unresectable Adrenocortical Cancer (ACC) — 0; 0; 13; 0 Participants
Breast Cancer
Primary: Response Rate (Complete and Partial, Confirmed and Unconfirmed) — 29 participants
Cicatrix · Dermabrasion · Coagulation, Laser
Primary: Safey Data Score Based on Ordinal Ratings of Erythema, Edema, Bleeding, Eschar After Resurfacing — 1.33; 3.00; 0; 0 units on a scale